HBV-IN-4

HBV-IN-4, a phthalazinone derivative, is a potent and orally active HBV DNA replication inhibitor with an IC 50 of 14 nM. HBV-IN-4 induces the formation of genome-free capsids and has potent anti- HBV potencies In Vitro HBV-IN-4 (compound 19f; 0-1 μM; 8 days) treatment inhibits the various forms (relaxed circular [rc] and single-stranded [ss] HBV DNA) in a dose-dependent manner in HepG2.2.15 cells. HBV-IN-4 treatment could also reduce capsidassociated DNAs dose-dependently. HBV-IN-4 could induce the formation of genome-free capsids, including a phenotype of faster-migrating ones. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo HBV-IN-4 (Compound 19f; 50-150 mg/kg; oral administration; twice a day; for 4 weeks; Balb/c male mice) treatment achieves 2.67 log viral load reduction in AAV-HBV/mouse model . HBV-IN-4 (compound 19f) exhibits favorable drug characteristics with low plasma clearance (CL=4.1 mL/min/kg), excellent drug exposure (AUC 0-t =49 744 h•ng/L), T 1/2 (2.15 hours) and oral bioavailability (F=60.4%) using 20 mg/kg oral administration in mice. HBV-IN-4 also shows good distribution in liver exposure . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Balb/c male mice (8-week-old) injected with a recombinant adenoassociated virus (AAV Dosage: 50 mg/kg, 150 mg/kg Administration: Oral administration; twice a day; for 4 weeks Result: Resulted in a 2.67 log reduction of the HBV DNA viral load during a 4-week treatment. Form:Solid IC50& Target:IC50: 14 nM (HBV DNA replication)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet